June 24, 2025

FDA Approves At-Home Lupus Nephritis Therapy

The FDA has approved a subcutaneous autoinjector of belimumab for at-home treatment of pediatric lupus nephritis.

Conexiant

June 19, 2025

GLP-1 Use Associated with Less Pain, Fatigue

At the EULAR 2025 Congress, researchers reported that GLP-1 receptor agonists were linked to reduced opioid use, pain, and fatigue in fibromyalgia patients based on a large real-world analysis.

Conexiant

June 17, 2025

Aconitine Tames Joints, Protects Bone

At EULAR 2025, researchers presented data showing aconitine reduced bone erosion and increased regulatory T cells in a rheumatoid arthritis mouse model.

Conexiant

June 16, 2025

Updated Guidance on Antirheumatic Drug Use

New 2024 EULAR recommendations offer evidence-based guidance for the use of antirheumatic drugs during pregnancy, lactation, and conception planning in patients with rheumatic and musculoskeletal diseases.

Conexiant

June 10, 2025

New Tool May Identify Patients at High Risk of Developing RA

New criteria may aid in identifying patients with joint pain who are at high risk of developing rheumatoid arthritis, enabling earlier intervention and better trial recruitment.

Conexiant

June 02, 2025

Only 20% Account for 80% of Steroid Use: Study

In a UK-wide analysis of nearly 2 million patients, researchers found that “a fifth of patients receiving corticosteroids accounted for over 80% of oral and inhaled corticosteroid prescribing,” highlighting concentrated use and variable treatment persistence across formulations.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

April 29, 2024

A Look Ahead at Rheumatology in 2024

A rheumatologist reflected on rheumatology developments in 2023 and looked ahead to the developments and challenges the field may face in 2024.

Conexiant

April 30, 2024

Potential New Lyme Disease Therapy Advances to Human Safety Trials

The novel antibiotic therapy hygromycin A has advanced to human safety trials to determine its potential as a future treatment for Lyme disease.

Conexiant